SELARSDI

Indicated For

Plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis

About This Medication

# SELARSDI Copay Card Patient Guide: How to Get SELARSDI (ustekinumab-aekn) at Low or No Cost SELARSDI (ustekinumab-aekn) is a biologic medication used to treat moderate to severe plaque psoriasis and active psoriatic arthritis in adults and children 6 years and older. The **SELARSDI Copay Card** from Teva Pharmaceuticals helps eligible patients reduce out-of-pocket costs for SELARSDI, potentially making it low or no cost with commercial insurance.[1][3][4] ## About SELARSDI (ustekinumab-aekn) **SELARSDI** is an injectable prescription medicine that targets the immune system to reduce inflammation. It is a biosimilar to Stelara (ustekinumab), offering a similar treatment option at potentially lower cost. SELARSDI is FDA-approved for: - Adults and pediatric patients (6 years and older) with **moderate to severe plaque psoriasis** who may benefit from phototherapy or systemic therapy.[3][4] - Adults and pediatric patients (6 years and older) with **active psoriatic arthritis**.[4] ### How It Works SELARSDI blocks proteins (interleukin-12 and interleukin-23) that cause inflammation in psoriasis and psoriatic arthritis. It is given as a subcutaneous injection (under the skin), typically starting with doses at Week 0 and Week 4, then every 12 weeks.[4] **Adult Dosing for Plaque Psoriasis**: - Patients ≤100 kg: 45 mg initially and at Week 4, then 45 mg every 12 weeks. - Patients >100 kg: 90 mg initially and at Week 4, then 90 mg every 12 weeks.[4] **Pediatric Dosing (6-17 years, Plaque Psoriasis)**: | Body Weight | Dose | |-------------|-----| | <60 kg | 0.75 mg/kg | | 60-100 kg | 45 mg | | >100 kg | 90 mg |[4] Your doctor will determine the right dose based on weight and condition. It can be self-injected after training or given by a healthcare provider.[2] ### Important Safety Information SELARSDI affects your immune system and may increase risks of **serious infections** (e.g., TB, bacterial, fungal, viral), cancers, allergic reactions, lung inflammation, or Posterior Reversible Encephalopathy Syndrome (PRES). Tell your doctor about infections, allergies, or other conditions before starting. Get screened for TB. Watch for symptoms like fever, cough, or shortness of breath.[1][2] ## Who Qualifies for the SELARSDI Copay Card? The **SELARSDI Copay Card** is designed for patients with **commercial private insurance**. It lowers copays or coinsurance for SELARSDI prescriptions, often to as low as $0-$5 per dose, up to a program maximum (exact limits not specified in sources).[1] **Key Eligibility**: - Valid prescription for SELARSDI. - Coverage under commercial insurance (not government insurance like Medicare/Medicaid). - U.S. resident. **Income Eligibility**: Specific income thresholds are **not specified** in available sources. This program focuses on copay assistance rather than strict FPL-based free medication. Contact Teva at 1-888-483-8279 to confirm if income affects eligibility.[1] **Income Eligibility Breakdown**: | Household Size | Income Threshold | FPL % | Notes | |----------------|------------------|-------|-------| | Individual | Not specified | Not specified | Copay assistance; income may not be primary factor | | Couple | Not specified | Not specified | Call 1-888-483-8279 for details | | Family of 3 | Not specified | Not specified | Commercial insurance required | | Family of 4 | Not specified | Not specified | Program details limited | Always verify with the program, as eligibility can change. ## Insurance Requirements - **Commercial/Private Insurance**: Required. The copay card works with most plans to cover copays/coinsurance.[1] - **Medicare/Medicaid/Government Insurance**: Typically **not eligible**. Medicare patients may need alternative programs.[1][2] - **Uninsured**: May not qualify; explore manufacturer patient assistance. ## Step-by-Step Application Process 1. **Get Prescribed**: Ask your doctor for SELARSDI if appropriate for your psoriasis or psoriatic arthritis. 2. **Check Eligibility**: Confirm commercial insurance coverage. Visit selarsdi.com or call **1-888-483-8279**.[1] 3. **Apply Online**: - Go to the SELARSDI support website (linked via selarsdi.com patient section). - Fill out the **online application** with your info, insurance details, and prescription.[1] - Your doctor/pharmacy may need to complete parts. 4. **Phone Option**: Call **1-888-483-8279** for help applying or questions (Mon-Fri, business hours). 5. **Receive Copay Card**: Digital card sent via email/text or physical card by mail. Activate at pharmacy. 6. **Fill Prescription**: Present card at pharmacy. Pay reduced copay (e.g., $0-$5, subject to max benefit). **Required Documents**: Not specified; likely insurance card, ID, proof of residency. Program may request income proof if applicable. Call to confirm.[1] ## Timeline and Delivery - **Processing Time**: Not specified; typically instant digital activation or 1-2 weeks for card.[1] - **Delivery**: Copay card via email/app for immediate use. Medication delivered via pharmacy specialty channel (e.g., self-inject or clinic).[2] - **Refills**: Card covers ongoing doses every 12 weeks; re-loads automatically if eligible.[1] ## Alternatives if Denied or Ineligible - **Biosimilar Alternative**: **Stelara (ustekinumab)** – reference product; similar efficacy/safety. May have its own Janssen CarePath program.[1] - **Other Options**: - Teva patient assistance programs (call 1-888-483-8279). - NeedyMeds.org or RxAssist.org for psoriasis biologics. - State programs or 340B clinics. - Generic topicals/systemics if appropriate. Discuss with your doctor. ## Disclaimer This guide is for informational purposes based on available sources as of 2026. Program details like copay max, exact eligibility, or changes are **not fully specified** in sources—**always contact Teva at 1-888-483-8279 or visit selarsdi.com for current info**. Not medical advice. Consult your healthcare provider before starting SELARSDI. Teva Pharmaceuticals not affiliated with this guide. Eligibility, benefits, and terms subject to change. See full Prescribing Information for risks.[1][2][3][4]

Program information last verified: March 30, 2026